OTCMKTS:CURLF - Curaleaf Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.69
  • Forecasted Upside: 85.78 %
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.43 (-3.26%)

This chart shows the closing price for CURLF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Curaleaf Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CURLF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CURLF

Analyst Price Target is $23.69
▲ +85.78% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Curaleaf in the last 3 months. The average price target is $23.69, with a high forecast of $32.25 and a low forecast of $16.00. The average price target represents a 85.78% upside from the last price of $12.75.

This chart shows the closing price for CURLF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 polled investment analysts is to buy stock in Curaleaf. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/7/2021Jefferies Financial GroupInitiated CoverageBuy$32.00
3/11/2021Canaccord GenuityBoost Price TargetBuy$23.50 ➝ $24.00
3/10/2021Cantor FitzgeraldBoost Price TargetOverweight$23.50 ➝ $26.50
3/10/2021Needham & Company LLCBoost Price TargetBuy$18.50 ➝ $19.75
3/8/2021BTIG ResearchInitiated CoverageBuy
2/25/2021Stifel NicolausBoost Price TargetBuy$23.00 ➝ $32.25
2/5/2021DA DavidsonReiterated RatingSell
1/26/2021Canaccord GenuityBoost Price TargetBuy$29.00
1/20/2021Roth CapitalBoost Price TargetBuy$14.00 ➝ $20.00
1/20/2021Cantor FitzgeraldBoost Price TargetOverweight$20.00 ➝ $23.50
1/19/2021Needham & Company LLCBoost Price TargetBuy$14.00 ➝ $18.50
1/13/2021Canaccord GenuityBoost Price TargetBuy$18.50 ➝ $23.50
12/3/2020Craig HallumInitiated CoverageBuy$19.00
11/18/2020Canaccord GenuityBoost Price TargetBuy$16.00 ➝ $18.50
11/18/2020Needham & Company LLCBoost Price TargetBuy$13.50 ➝ $14.00
11/18/2020Cantor FitzgeraldBoost Price TargetOverweight$18.00 ➝ $20.00
8/18/2020Canaccord GenuityBoost Price TargetBuy$15.00 ➝ $16.00
8/18/2020Alliance Global PartnersBoost Price TargetBuy$14.00 ➝ $16.00
8/18/2020Needham & Company LLCBoost Price TargetBuy$11.00 ➝ $13.50
8/18/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$18.00
8/6/2020Needham & Company LLCBoost Price TargetBuy$10.70 ➝ $11.00
8/4/2020Cantor FitzgeraldBoost Price TargetNeutral$7.50 ➝ $10.00
7/23/2020Alliance Global PartnersBoost Price TargetBuy$12.00 ➝ $14.00
7/22/2020Stifel NicolausInitiated CoverageBuy
6/22/2020Needham & Company LLCReiterated RatingBuy$10.70
6/8/2020Roth CapitalInitiated CoverageBuy$9.00
5/19/2020Cantor FitzgeraldBoost Price TargetNeutral$6.00 ➝ $7.50
5/19/2020Needham & Company LLCBoost Price TargetBuy$5.90 ➝ $10.10
5/19/2020Canaccord GenuityReiterated RatingBuy$15.00
5/12/2020Needham & Company LLCBoost Price TargetBuy$5.50 ➝ $5.90
3/25/2020Cantor FitzgeraldBoost Price TargetNeutral$4.10 ➝ $4.70
3/17/2020Needham & Company LLCLower Price TargetBuy$8.80 ➝ $5.50
2/13/2020Cantor FitzgeraldInitiated CoverageNeutral$8.60
2/11/2020Alliance Global PartnersInitiated CoverageBuy
12/23/2019Needham & Company LLCReiterated RatingBuy$7.25
12/3/2019Needham & Company LLCInitiated CoverageBuy$7.25
11/6/2019MKM PartnersUpgradeSell ➝ Neutral
9/20/2019MKM PartnersInitiated CoverageSell$5.00
9/13/2019CowenInitiated CoverageOutperform$11.00
6/10/2019Compass PointInitiated CoverageBuy
2/21/2019Seaport Global SecuritiesInitiated CoverageBuy
(Data available from 7/25/2016 forward)
Curaleaf logo
Curaleaf Holdings, Inc. operates as an integrated medical and wellness cannabis operator in the United States. It operates in two segments, Cannabis Operations and Non-Cannabis Operations. The Cannabis Operations segment engages in the production and sale of cannabis through retail and wholesale channels. The Non-Cannabis Operations segment provides professional services, including cultivation, processing, and retail know-how and back office administration, intellectual property licensing, real estate leasing services, and lending facilities to medical and adult-use cannabis licensees under management service agreements. It offers oil-based formulations, such as vaporizing, cartridges, tinctures, and capsules; and ground-flower. The company also provides hemp-based CBD products. As of March 9, 2021, it operated 101 dispensaries, 23 cultivation sites, and 30 processing sites in 23 states of the United States. The company was founded in 2010 and is headquartered in Wakefield, Massachusetts.
Read More

Today's Range

Now: $12.75
Low: $12.72
High: $13.35

50 Day Range

MA: $14.15
Low: $12.72
High: $15.13

52 Week Range

Now: $12.75
Low: $5.81
High: $18.38


424,587 shs

Average Volume

1,017,126 shs

Market Capitalization


P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Curaleaf?

The following equities research analysts have issued research reports on Curaleaf in the last year: Alliance Global Partners, BTIG Research, Canaccord Genuity, Cantor Fitzgerald, Craig Hallum, DA Davidson, Jefferies Financial Group Inc., Needham & Company LLC, Roth Capital, and Stifel Nicolaus.
View the latest analyst ratings for CURLF.

What is the current price target for Curaleaf?

8 Wall Street analysts have set twelve-month price targets for Curaleaf in the last year. Their average twelve-month price target is $23.69, suggesting a possible upside of 85.8%. Stifel Nicolaus has the highest price target set, predicting CURLF will reach $32.25 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $16.00 for Curaleaf in the next year.
View the latest price targets for CURLF.

What is the current consensus analyst rating for Curaleaf?

Curaleaf currently has 1 sell rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CURLF will outperform the market and that investors should add to their positions of Curaleaf.
View the latest ratings for CURLF.

What other companies compete with Curaleaf?

How do I contact Curaleaf's investor relations team?

The company's listed phone number is 781-451-0150. The official website for Curaleaf is www.curaleaf.com.